A subcutaneous insulin pharmacokinetic model for computer simulation in a diabetes decision support role: Validation and simulation

Abstract

Objective: The goal of this study was to validate a previously derived and identifed physiological subcutaneous (SC) insulin absorption model for computer simulation in a clinical diabetes decision support role using published pharmacokinetic summary measures. Methods: Validation was performed using maximal plasma insulin concentration (Cmax) and time to maximal concentration (tmax) pharmacokinetic summary measures. Values were either reported or estimated from 37 pharmacokinetic studies over six modeled insulin types. A validation comparison was made to equivalent pharmacokinetic summary measures calculated from model generated curves ftted to respective plasma insulin concentration data. The validation result was a measure of goodness of ft. Validation for each reported study was classifed into one of four cases. Results: Of 37 model fts, 22 were validated on both the C maxand the tmaxsummary measures. Another 6 model fts were partially validated on one measure only due to lack of reporting on the second measure with errors to reported or estimated ranges of <12%. Another 7 studies could not be validated on either measure because of inadequate reported clinical data. Finally, 2 separate model fts to data from the same study failed the validation with 90 and 71% error on tmaxonly, which was likely caused by protocol-based error. No model ft failed the validation on both measures. Conclusions: A previously derived and identifed model was clinically validated for six insulin types using Cmaxand tmaxsummary measures from published pharmacokinetic studies. Hence, this article presents a clinically valid model that accounts for multiple nonlinear effects and six different types of SC insulin in a computationally modest form suitable for use in clinical decision support.© Diabetes Technology Society.